Specify Company / Ticker to Get the Summary
Dividend History INBX
Dividend Analytics INBX
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Inhibrx Biosciences, Inc.
INBXInhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California. Address: 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037
Analytics
WallStreet Target Price
12.00 USDP/E Ratio
0.13Dividend Yield
–Financials INBX
Results | 2019 | Dynamics |